Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Abstract Background In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we examined the effect of erenumab on reducing acute...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Hernan Picard, Sunfa Cheng, Denise E Chou, Feng Zhang, Jan Klatt, Daniel D Mikol
Formaat: Artikel
Taal:English
Gepubliceerd in: BMC 2021-07-01
Reeks:The Journal of Headache and Pain
Onderwerpen:
CGRP receptor
Chronic migraine
Episodic migraine
Erenumab
Migraine-specific
Online toegang:https://doi.org/10.1186/s10194-021-01292-w

Internet

https://doi.org/10.1186/s10194-021-01292-w

Gelijkaardige items